Entrectinib Phase 1/2 Study in Pediatric Solid Tumors and CNS Tumors Initiated
A Phase 1/2 study of Entrectinib in pediatric patients with advanced solid tumors and CNS tumors has been initiated.
Therapeutic Area
Therapeutic area intelligence for Solid Tumors and CNS Tumors with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.